10.5061/DRYAD.DR7SQV9VS
Lee, Jin San
0000-0002-5017-854X
Kyung Hee University
Lee, Hyejoo
Samsung Medical Center
Park, Seongbeom
Samsung Medical Center
Choe, Yeongsim
Samsung Medical Center
Park, Yu Hyun
Samsung Medical Center
Cheon, Bo Kyoung
Samsung Medical Center
Hahn, Alice
Samsung Medical Center
Ossenkoppele, Rik
VU University Medical Center
Kim, Hee Jin
Samsung Medical Center
Kim, Seonwoo
Samsung Medical Center
Yoo, Heejin
Samsung Medical Center
Jang, Hyemin
Samsung Medical Center
Cho, Soo Hyun
Chonnam National University Medical School
Kim, Seung Joo
Gyeongsang National University School of Medicine
Kim, Jun Pyo
Samsung Medical Center
Jung, Young Hee
Myungji Hospital
Park, Key-Chung
Kyung Hee University
DeCarli, Charles
University of California, Davis
Weiner, Michael
University of California, San Francisco
Na, Duk L.
Samsung Medical Center
Seo, Sang Won
Samsung Medical Center
Data from: Distinct association between APOE ε2 and Aβ in Alzheimer- and
vascular-type cognitive impairment
Dryad
dataset
2020
2021-07-10T00:00:00Z
2021-07-10T00:00:00Z
en
47323 bytes
2
CC0 1.0 Universal (CC0 1.0) Public Domain Dedication
Objective: To investigate the association between apolipoprotein E (APOE)
genotype and amyloid-β (Aβ) burden, as measured by PET in patients with
subcortical vascular cognitive impairment (SVCI) and those with
Alzheimer’s disease-related cognitive impairment (ADCI). Methods: This was
a cross-sectional study of 310 patients with SVCI and 999 with ADCI. To
evaluate the effects of APOE genotype or diagnostic group on
Aβ-positivity, we performed multivariate logistic regression analyses.
Further distinctive underlying features of latent subgroups were examined
by employing a latent class cluster analysis approach. Results: In
comparison with ε3 homozygotes, in the ADCI group, ε2 carriers showed a
lower frequency of Aβ-positivity (odds ratio [OR] 0.43, 95% CI 0.23–0.79)
while in the SVCI group, ε2 carriers showed a higher frequency of
Aβ-positivity (OR 2.26, 95% CI 1.02–5.01). In particular, we observed an
interaction effect of ε2 carrier status and diagnostic group on
Aβ-positivity (OR 5.12, 95% CI 1.93–13.56), in that relative to ε3
homozygotes, there were more Aβ-positive ε2 carriers in the SVCI group
than in the ADCI group. We also identified latent subgroups of Aβ-positive
APOE ε2 carriers with SVCI and Aβ-positive APOE ε4 carriers with ADCI.
Conclusions: Our findings suggest that APOE ε2 shows distinctly associated
with Aβ deposition in patients with SVCI and those with ADCI. Our findings
further suggest that there is a distinctive subgroup of Aβ-positive APOE
ε2 carriers with SVCI among patients with cognitive impairments.